

## Introduction

Elevated protease activity (EPA) may disrupt wound healing. This Made Easy describes the types of wounds that may have EPA and how wounds with EPA may be identified. The methods that may be used to reduce protease activity to a level where healing can progress are also discussed.

*Authors: Dissemond J, Dowsett C, Schultz G, Serena T. Full author details can be found on page 5.*

## What are proteases?

Proteases are a group of enzymes that act on proteins. They generally cut a protein into two or more pieces, and so change its structure. For some proteins this results in loss of function, but for others it may result in activation of a molecule that interacts with other molecules, eg another enzyme or a receptor. Proteases may have a specific substrate, ie they may act on only one specific protein, or they may be able to act on a range of proteins.

Some proteases have key roles in wound healing. However, in high levels some have been implicated in delayed healing. The major groups of proteases involved in wound healing are the matrix metalloproteases and the serine proteases.

### Matrix metalloproteases

Matrix metalloproteases (MMPs) all contain a zinc atom (hence the metallo- prefix). They preferentially break down the proteins comprising the extracellular matrix (ECM), and together can act on all ECM components, eg collagens, elastin and glycoproteins. So far, 23 human MMPs have been identified, with MMP-1, MMP-2, MMP-8 and MMP-9 the particular focus of wound-related research<sup>1</sup>.

### Serine proteases

There are numerous serine proteases involved in wound healing, with human neutrophil elastase (HNE) predominating<sup>2</sup>. This enzyme is able to act on a wide range of proteins in the ECM and also on inflammatory mediators<sup>3</sup>.

## What are the roles of proteases in wound healing?

Proteases have a number of functions in the inflammatory, proliferative and remodelling phases of normal wound healing. Broadly, in normal wound healing they break down damaged ECM and foreign material, aiding new tissue formation and orderly wound closure. It is widely recognised, however, that in excess, proteases can have a detrimental effect on wound healing.

## What affects protease activity?

The production and regulation of proteases is complex. MMPs are produced by tissue cells involved in healing, eg neutrophils, fibroblasts, endothelial cells and epithelial cells. They are also produced by immune cells as part of the inflammatory process or in response to infection. As the name suggests, HNE is produced by neutrophils.

When first produced, MMPs are usually in an inactive (pro-MMP) form. They are subsequently activated by other proteases and by serine proteases such as HNE.

Tissue inhibitors of metalloproteases (TIMPs), which are produced by a variety of tissue cells, inhibit the activation of pro-MMPs and also the activity of activated MMPs. The main inhibitor of HNE is  $\alpha$ -1 protease inhibitor (also known as  $\alpha$ -1 antitrypsin), which is secreted by macrophages and liver cells<sup>4</sup>.

The presence of bacteria in wounds may increase protease activity. The bacteria induce an inflammatory response that stimulates protease production. In addition, bacteria may also produce proteases<sup>5</sup>.

## How do proteases sometimes cause problems with healing?

Proteases are essential for normal healing. However, it is widely recognised that protease activity, including that of the MMPs and HNE, is elevated in wounds that are failing to progress<sup>6-11</sup>.

In normal wound healing, an initial rapid rise in protease activity starts to reduce by about day five. In non-healing wounds, protease activity reaches higher levels and persists for longer<sup>12</sup>.

Elevated protease activity may result in 'off target' destruction of proteins that are essential for healing, such as growth factors, receptors and newly formed ECM. This may disturb the balance between ECM deposition and destruction<sup>5</sup>.

The damaging effects of the proteases may further stimulate the inflammatory response and release of damaging reactive oxygen species. The resulting excess protease activity causes the wound to enter a vicious circle (Cullen's circle) that ultimately delays healing (Figure 1, see page 2). High wound bioburden may augment the circle through the production of bacterial proteases that further stimulate the inflammatory response.

## Which sorts of wounds are affected by high protease activity?

Studies have noted high levels of protease activity in chronic wounds

of widely differing aetiology, eg venous leg ulcers, diabetic foot ulcers, pressure ulcers and trauma wounds<sup>11,13-15</sup>. This suggests that high protease activity is related to a problem with the healing process itself rather than with the aetiology of the wound.

## How high is too high?

For clinicians to effectively target high protease levels, they need to know at what level protease activity is likely to start to cause harm, and to be able to easily identify affected wounds.

A recent study has examined the correlation between HNE and MMP activity and healing rates in a range of chronic wounds<sup>16</sup>. Likelihood of healing was determined by measuring changes in wound area over two to four weeks. A reduction of 50% or more for diabetic foot ulcers, or of 30% or more for venous leg ulcers and pressure ulcers, was considered indicative of healing.

The study found that a wound had a 90% probability of being classified as non-healing when HNE activity was  $\geq 25\text{mU}/110\mu\text{l}$  and/or total MMP activity was  $\geq 48\text{U}/110\mu\text{l}$ <sup>16</sup>. Protease activity at or above these levels has therefore been determined to indicate elevated protease activity (EPA) and a 90% probability of non-healing.

## How many wounds are affected by EPA?

Multicentre studies in the USA found the prevalence of EPA to be 25-28% of non-healing wounds<sup>15,16</sup>. The wounds included in these

studies were classified as non-healing according to clear criteria related to changes in wound area over two to four weeks. When healing wounds were included in the analysis from the first study, the prevalence of EPA was 22%.

In addition, wounds of any duration may have EPA and EPA may be present in all common chronic wound types, ie leg ulcers, diabetic foot ulcers, pressure ulcers and trauma wounds<sup>15</sup>.

## What might affect prevalence of EPA?

The prevalence of any condition is subject to variation between studies as a result of a number of factors, eg differences in the population studied, the criteria for inclusion and the measurement methods used. So the prevalence of EPA measured in different care settings may be affected by a range of issues including:

- whether healing wounds are included
- whether the criteria for non-healing have been applied consistently
- the treatment regimen being used prior to testing, eg whether protease modulating dressings have been used
- whether sample collection and test procedures have been followed correctly.

## Testing for EPA

Not all wounds with delayed healing have EPA. Therefore, clinicians need to be able to identify which wounds have EPA to be able to use protease modulating strategies effectively. However, there are no visual clues specific to EPA and it is not possible for clinicians to determine EPA from a visual examination alone<sup>18,19</sup>.


The availability of a diagnostic test that clinicians can use to reliably detect EPA and to indicate appropriate treatment has the potential to have a considerable impact on clinical and economic outcomes<sup>20-22</sup>.

Until recently, measurement of protease activity has been a laboratory procedure that has been used for research purposes. However, an easy to use point of care test for EPA — WOUNDCHEK™ Protease Status (Systagenix) — is now available and in clinical use.

## How to use WOUNDCHEK™ Protease Status

WOUNDCHEK™ Protease Status is a point of care test that uses wound fluid swabbed from chronic wounds. The test takes about 15 minutes.

**Figure 1** Cullen's circle – the vicious circle of delayed wound healing<sup>17</sup>





responding to treatment or has stalled, can be determined by reduction in wound area over two to four weeks.

For venous leg ulcers and pressure ulcers, an area reduction of 20–40% in two to four weeks has been found to be predictive of healing<sup>23–26</sup>. For diabetic foot ulcers, a wound area reduction of  $\geq 50\%$  by week four is predictive of healing<sup>27–30</sup>.

### How soon can we test for EPA?

Non-response to treatment may become apparent within two to four weeks, depending on wound aetiology. Therefore, testing for EPA may be useful after two to four weeks of standard care as part of the process of re-evaluating the wound, the patient and the treatment.

Currently, it is not known how soon EPA may occur after a wound develops and therefore when it may be appropriate to test for EPA. However, a study of the prevalence of EPA found that wounds of any duration may have EPA<sup>15</sup>.

Once a wound has been shown to have EPA, an appropriate strategy for reducing protease activity can be implemented. The strategy should take into account the care setting and the needs of the patient and the wound, eg whether treatment for infection is also necessary (Figure 2, see page 3).

### What can be done about EPA?

Recognising EPA in a wound with delayed healing will help the clinician to identify which treatments are appropriate.

Treatment to reduce elevated protease activity should take place in the context of a full assessment and an appropriate local wound care protocol<sup>12</sup>.

Treatment of the underlying cause of the wound and any factors or comorbidities that may be contributing to perpetuation of the wound, along with optimisation of

the wound bed and patient, must underpin treatment to reduce protease activity.

Approaches to reducing protease activity may include:

- **reducing protease production** by reducing inflammation, eg where appropriate:
  - removing necrotic wound tissue (eg debridement)
  - reducing wound bioburden (eg antimicrobial dressings)
  - dampening the immune response (eg oral/topical doxycycline<sup>31</sup> or steroids)
- **removal of proteases from the wound bed** eg cleansing, absorbent dressings and negative pressure wound therapy (NPWT)<sup>32</sup>
- **reducing protease activity** eg collagen/oxidised regenerated cellulose (ORC) dressings (evidence discussed below).

### Protease modulating dressings

There are many dressings marketed as modulating protease activity. Some reduce protease activity by absorbing wound exudate and so removing proteases and/or inflammatory mediators from the wound bed; others also act directly by binding or inactivating proteases<sup>19</sup>.

There are varying levels of clinical evidence for protease modulating dressings. The action of some dressings is supported by *in vitro* studies only, while other dressings have a wide range of evidence including the results of randomised controlled clinical trials<sup>33,34</sup>.

When choosing which dressing to use to modulate protease activity, clinicians need to choose a formulation or a combination of primary and secondary dressings that also meets the other needs of the wound and the patient. For example, should the dressing be suitable for use under compression, does the dressing also need to have antimicrobial activity because the wound is infected, does the patient have fragile skin that requires a

dressing with low adhesive fixation, or does the dressing have the right absorbency for the level of exudate production?

An international consensus recommended that protease modulating dressings should be used for short courses of two to four weeks, followed by a full reassessment<sup>12</sup>.

### Collagen/ORC dressings

Dressings containing collagen/ORC have been shown to reduce the activity of MMPs and serine proteases, as well as levels of inflammatory cytokines in a range of chronic wounds<sup>2,34–37</sup>.

An *in vitro* study of the effect of a variety of dressings against MMP and elastase activity in chronic wound fluid taken from wounds with EPA, found that collagen/ORC and collagen/ORC/silver dressings performed significantly better than dressings containing collagen only or nano-oligosaccharide factor (NOSF)<sup>38</sup>.

A recent retrospective analysis of venous leg ulcers treated with a collagen/ORC dressing +/- silver showed that wounds which had EPA at the start of treatment had a 22% higher response rate at 4 weeks (77% of wounds with EPA responded vs 63% of all wounds in the study)<sup>39</sup>. This suggests that response rates to collagen/ORC dressings may be improved by targeting treatment to wounds shown to have EPA. The case study (see page 5) is an example of the use of targeted treatment of EPA with a collagen/ORC dressing in a patient with a venous leg ulcer.

### Retesting for EPA

An international consensus has suggested that retesting for EPA should take place two to four weeks after initial detection of EPA (Figure 2, see page 3). If EPA remains, then the wound, patient and treatment regimen should be reassessed, with an emphasis on determining if infection is present. If EPA has resolved and healing progress is satisfactory, it is not yet clear at what point

discontinuation of protease modulating therapy can be considered. If EPA is no longer present, but the wound is still not healing, a full review should be conducted.

## What do we know about EPA and bioburden?

Although wound bioburden may raise protease activity, diagnosis of wound infection is made clinically and detection of EPA (ie human inflammatory protease activity) cannot be taken to be confirmation of increased wound bioburden or wound infection.

Further research is required to clarify the impact of raised protease activity resulting from wound bioburden, and whether distinguishing this activity from EPA due to delayed wound healing is feasible and relevant.

## What are the benefits of testing for EPA and of targeted treatment?

Wounds with delayed healing are enormously costly to healthcare systems and to patients. It is logical that a test for EPA, which can direct the clinician to appropriate protease modulating treatment, will bring financial and social benefits and

improved utilisation of healthcare resources through:

- fewer dressing changes
- reduced nursing time and fewer clinic visits
- avoidance of unnecessary interventions
- avoidance of more invasive and expensive diagnostic tests, eg wound biopsy
- earlier identification and prevention of complications
- shorter overall treatment duration
- improved quality of life
- earlier return to work<sup>12</sup>.

An economic model based on the UK healthcare system in which 100 chronic wounds were not tested for EPA has estimated that undiagnosed EPA could waste about £126,000<sup>40</sup>.

## The future of testing for EPA

As research continues, the role for an EPA test in clinical practice will evolve. Specific areas for further investigation include:

- Why and at what point on the healing trajectory protease activity may become imbalanced
- If there are any differences in the protease profile of wounds of

different aetiologies and in the various phases of wound healing

- The relationship between EPA and wound bioburden
- The impact on healing and economic outcomes of testing for EPA and protease management
- The relationship between wound duration and EPA in different wound types
- If there is a role for testing for EPA in acute wounds
- How patient factors such as age and co-morbidities affect protease activity
- Why some healing wounds have EPA and what implications this has on management
- Which are the most effective treatments for EPA.

## Author details

Dissemond J<sup>1</sup>, Dowsett C<sup>2</sup>, Schultz G<sup>3</sup>, Serena T<sup>4</sup>.

1. Dermatology and Venerology Consultant, Department of Dermatology, University Hospital of Essen, Germany
2. Nurse Consultant Tissue Viability, Community Health Newham Directorate, East London NHS Foundation Trust/Tissue Viability Service, East Ham Care Centre, London, UK
3. Professor, Institute for Wound Research, Department of Obstetrics and Gynecology, University of Florida, Gainesville, Florida, USA
4. Medical Director, Pennsylvania North Centers for Advanced Wound Care, Pennsylvania, USA

### CASE STUDY: NON-HEALING VENOUS LEG ULCER WITH EPA

#### Background

Mr F, aged 69 years, presented with a non-healing venous leg ulcer on the left medial malleolus that had been unresponsive to treatment with compression therapy and various dressings. There was no evidence of wound infection. A WOUNDCHek™ Protease Status test showed elevated protease activity (EPA).

#### Treatment

The wound was treated with a protease modulating collagen/ORC dressing (PROMOGRAN®) and multi-layer compression bandaging.

#### Outcome

After two weeks of treatment, the condition of the wound bed had improved and the wound had reduced in size. The protease modulating dressing was discontinued and the wound was fully healed six weeks after treatment started.



Fig 1: Venous leg ulcer at baseline



Fig 2: Venous leg ulcer after two weeks of treatment with a protease modulating dressing

Acknowledgement: Dr Caroline Dowsett, Newham, London

## References

1. Moali C, Hulmes DJS. Extracellular and cell surface proteases in wound healing: new players are still emerging. *Eur J Dermatol* 2009; 19(6): 552–64.
2. Cullen B, Smith R, McCulloch E, et al. Mechanism of action of PROMOGRAN®, a protease modulating matrix, for the treatment of diabetic foot ulcers. *Wound Repair Regen* 2002; 10: 16–25.
3. Lee WL, Downey GP. Leukocyte elastase. Physiological functions and role in acute lung injury. *Am J Respir Crit Care Med* 2001; 164: 896–904.
4. Rai RR, Phadke MS. Plasma antiprotease status in different respiratory disorders. *Internet J Pulmon Med* 2007; 7(1): DOI: 10.5580/1d0 Available from <http://tinyurl.com/9wwwgeh3>
5. McCarty SM, Cochrane CA, Clegg PD, Percival SL. The role of endogenous and exogenous enzymes in chronic wounds: a focus on the implications of aberrant levels of both host and bacterial proteases in wound healing. *Wound Repair Regen* 2012; 20(2): 125–36.
6. Rao CN, Ladin DA, Liu YY, et al. Alpha 1–antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. *J Invest Dermatol* 1995; 105(4): 572–78.
7. Yager DR, Zhang LY, Liang HX. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. *J Invest Dermatol* 1996; 107(5): 743–48.
8. Ladwig GP, Robson MC, Liu R, et al. Ratios of activated matrix metalloproteinase–9 to tissue inhibitor of matrix metalloproteinase–1 in wound fluids. *Wound Repair Regen* 2002; 10(1): 26–37.
9. Pirttilä E, Korpi JT, Korkiamäki T, et al. Collagenase–2 (MMP–8) and matrilysin–2 (MMP–26) expression in human wounds of different etiologies. *Wound Repair Regen* 2007; 15(1): 47–57.
10. Rayment EA, Upton Z, Shooter GK. Increased matrix metalloproteinase–9 (MMP–9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. *Br J Dermatol* 2008; 158(5): 951–61.
11. Liu Y, Min D, Bolton T, et al. Increased matrix metalloproteinase–9 predicts poor wound healing in diabetic foot ulcers. *Diabetes Care* 2009; 32(1): 117–19.
12. International consensus. The role of proteases in wound diagnostics. An expert working group review. London: *Wounds International*, 2011.
13. Trengove NJ, Stacey MC, Macauley S, et al. Analysis of acute and chronic wound environments: the role of proteases and their inhibitors. *Wound Rep Reg* 1999; 7: 442–52.
14. Beidler SK, Douillet CD, Berndt DF, et al. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. *Wound Repair Regen* 2008; 16(5): 642–48.
15. Serena T, Harding K, Queen D, et al. *Preliminary results: testing for elevated protease activity in clinical practice*. Poster presented at: Wounds UK, Harrogate, 2012.
16. Serena T, Cullen B, Bayliff S, et al. *Protease activity levels associated with healing status of chronic wounds*. Poster presented at: SAWC, Baltimore, 2012.
17. Gibson D, Cullen B, Legerstee R, et al. MMPs Made Easy. *Wounds International* 2009; 1(1): Available from <http://www.woundsinternational.com>
18. Snyder RJ, Cullen B, Nisbet LT. An audit to assess the perspectives of US wound care specialists regarding the importance of proteases in wound healing and wound assessment. *Int Wound J* 2012 Jul 29. doi: 10.1111/j.1742–481X.2012.01040.x. [Epub ahead of print]
19. Young T. Using a protease test to inform wound care treatments decisions. *Wounds UK* 2012; 8(4): 74–80.
20. World Union of Wound Healing Societies (WUWHS). *Principles of best practice: Diagnostics and wounds. A consensus document*. London: MEP Ltd, 2008.
21. Snyder RJ, Driver V, Fife CE, et al. Using a diagnostic tool to identify elevated protease activity levels in chronic and stalled wounds: a consensus panel discussion. *Ostomy Wound Manage* 2011; 57(12): 36–46.
22. Strohal R, Dissemond J, Hastermann K, et al. The role of a point-of-care protease test in wound diagnostics. *WundManagement* 2012; 6(Suppl): 1–12.
23. Arnold T, Stanley JC, Fellowes EP, et al. Prospective, multicenter study of managing lower extremity venous ulcers. *Ann Vasc Surg* 1994; 8: 355–62.
24. Tallman P, Muscare E, Carson P, Eaglstein WH, Falanga V. Initial rate of healing predicts complete healing of venous ulcers. *Arch Dermatol* 1997; 133(10): 1231–34.
25. Günes UY. A prospective study evaluating the pressure ulcer scale for healing (PUSH tool) to assess stage II, stage III and stage IV pressure ulcers. *Ostomy Wound Manage* 2009; 55(5): 48–52.
26. Gelfand JM, Holstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. *J Invest Dermatol* 2002; 119: 1420–25.
27. Sheehan P, Jones P, Caselli D, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. *Diabetes Care* 2003; 26: 1879–82.
28. Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. *Diabetes Care* 2003; 26(6): 1696–700.
29. Coerper S, Beckert S, Küper MA, Jekov M, Königsrainer A. Fifty percent area reduction after 4 weeks of treatment is a reliable indicator for healing – analysis of a single-center cohort of 704 diabetic patients. *J Diabetes Complications* 2009; 33(2): 49–53.
30. Snyder RJ, Cardinal M, Dauphinée DM, Stavosky J. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. *Ostomy Wound Manage* 2010; 56(3): 44–50.
31. Stechmiller J, Cowan L, Schultz G. The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. *Biol Res Nurs* 2010; 11(4): 336–44.
32. Kirby M. Negative pressure wound therapy. *Br J Diabetes Vasc Dis* 2007; 7: 230–34.
33. Lázaro-Martínez JL, García-Morales E, Beneit-Montesinos JV, et al. [Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers]. *Cir Esp* 2007; 82(1): 27–31.
34. Gottrup F, Cullen BM, Karlsmark T, et al. Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. *Wound Repair Regen* 2013; 21(2): 216–25.
35. Smeets R, Ulrich D, Unglaub F, et al. Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. *Int Wound J* 2008; 5(2): 195–203.
36. Cullen B, Kemp L, Essler L, et al. Rebalancing wound biochemistry improves healing: a clinical study examining effect of PROMOGRAN®. *Wound Repair Regen* 2004; 12(2): A4.
37. Cullen B, Ivins N. PROMOGRAN® & PROMOGRAN Prisma® Made Easy. *Wounds International* 2010; 1(3): Available from <http://www.woundsinternational.com>
38. Cullen B, Gibson M, Bartle C, et al. An *in vitro* model to evaluate the ability of collagen/ORC dressings to rebalance the non-healing wound environment. Poster presented at: SAWC, Baltimore 2012.
39. Cullen B, Gibson M, Nesbit L. Targeted use of protease modulating dressings improves clinical outcomes. Presented at Wounds UK, Harrogate 2011.
40. Dowsett C. The role of wound diagnostics in treating chronic wounds predictably and cost-effectively. In: *Evidence-based wound management in primary care*. Surrey: Global Business Media 2013:10–11. Available at: [www.primarycarereports.co.uk](http://www.primarycarereports.co.uk)

Supported by an educational grant from Systagenix. The views expressed in this Made Easy do not necessarily reflect those of Systagenix.

## Summary

Wounds with elevated protease activity (EPA), and therefore at risk of delayed healing, can now be readily identified using the WOUNDCEK™ Protease Status point of care test. The wounds identified as having EPA can receive targeted treatment to modulate protease activity with the expectation that both clinical and economic outcomes will be improved.

### To cite this publication

Dissemond J, Dowsett C, Schultz G, Serena T. EPA Made Easy. *Wounds International* 2013; 4(1): Available from <http://www.woundsinternational.com>